+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Induced Pluripotent Stem Cell (iPSC) - Global Market Trajectory & Analytics

  • PDF Icon

    Report

  • 349 Pages
  • October 2022
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 4805485

Global Induced Pluripotent Stem Cell ((iPSC) Market to Reach $0 Thousand by 2027

Amid the COVID-19 crisis, the global market for Induced Pluripotent Stem Cell ((iPSC) estimated at US$1.4 Billion in the year 2020, is projected to reach a revised size of US$0 Thousand by 2027, growing at a CAGR of -100% over the period 2020-2027. Vascular Cells, one of the segments analyzed in the report, is projected to record a -100% CAGR and reach US$0 Thousand by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cardiac Cells segment is readjusted to a revised -100% CAGR for the next 7-year period.

The U.S. Market is Estimated at $629.2 Million, While China is Forecast to Grow at -100% CAGR

The Induced Pluripotent Stem Cell ((iPSC) market in the U.S. is estimated at US$629.2 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$0 Thousand by the year 2027 trailing a CAGR of -100% over the period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at -100% and -100% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately -100% CAGR.

Neuronal Cells Segment to Record -100% CAGR

In the global Neuronal Cells segment, USA, Canada, Japan, China and Europe will drive the -100% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$188.9 Million in the year 2020 will reach a projected size of US$0 Thousand by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 51 Featured)

  • Axol Bioscience Ltd.
  • Cynata Therapeutics Limited
  • Evotec SE
  • Fate Therapeutics, Inc.
  • FUJIFILM Cellular Dynamics, Inc.
  • Ncardia
  • Pluricell Biotech
  • REPROCELL USA, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • ViaCyte, Inc.

What's New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to a digital archives and Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Impact of Covid-19 and a Looming Global Recession
  • Induced Pluripotent Stem Cells (iPSCs) Market Gains from Increasing Use in Research for COVID-19
  • Studies Employing iPSCs in COVID-19 Research
  • Stem Cells, Application Areas, and the Different Types: A Prelude
  • Applications of Stem Cells
  • Types of Stem Cells
  • Induced Pluripotent Stem Cell (iPSC): An Introduction
  • Production of iPSCs
  • First & Second Generation Mouse iPSCs
  • Human iPSCs
  • Key Properties of iPSCs
  • Transcription Factors Involved in Generation of iPSCs
  • Noteworthy Research & Application Areas for iPSCs
  • Induced Pluripotent Stem Cell ((iPSC) Market: Growth Prospects and Outlook
  • Drug Development Application to Witness Considerable Growth
  • Technical Breakthroughs, Advances & Clinical Trials to Spur Growth of iPSC Market
  • North America Dominates Global iPSC Market
  • Competition
  • Recent Market Activity
  • Select Innovation/Advancement
  • Induced Pluripotent Stem Cell (iPSC) - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
  • Axol Bioscience Ltd. (UK)
  • Cynata Therapeutics Limited (Australia)
  • Evotec SE (Germany)
  • Fate Therapeutics, Inc. (USA)
  • FUJIFILM Cellular Dynamics, Inc. (USA)
  • Ncardia (Belgium)
  • Pluricell Biotech (Brazil)
  • REPROCELL USA, Inc. (USA)
  • Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Takara Bio, Inc. (Japan)
  • Thermo Fisher Scientific, Inc. (USA)
  • ViaCyte, Inc. (USA)
3. MARKET TRENDS & DRIVERS
  • Effective Research Programs Hold Key in Roll Out of Advanced iPSC Treatments
  • Induced Pluripotent Stem Cells: A Giant Leap in the Therapeutic Applications
  • Research Trends in Induced Pluripotent Stem Cell Space
  • Worldwide Publication of hESC and hiPSC Research Papers for the Period 2008-2010, 2011-2013 and 2014-2016
  • Number of Original Research Papers on hESC and iPSC Published Worldwide (2014-2016)
  • Concerns Related to Embryonic Stem Cells Shift the Focus onto iPSCs
  • Regenerative Medicine: A Promising Application of iPSCs
  • Induced Pluripotent: A Potential Competitor to hESCs?
  • Global Regenerative Medicine Market Size in US$ Billion for 2019, 2021, 2023 and 2025
  • Global Stem Cell & Regenerative Medicine Market by Product (in %) for the Year 2019
  • Global Regenerative Medicines Market by Category: Breakdown (in %) for Biomaterials, Stem Cell Therapies and Tissue Engineering for 2019
  • Pluripotent Stem Cells Hold Significance for Cardiovascular Regenerative Medicine
  • Leading Causes of Mortality Worldwide: Number of Deaths in Millions & % Share of Deaths by Cause for 2017
  • Leading Causes of Mortality for Low-Income and High-Income Countries
  • Growing Importance of iPSCs in Personalized Drug Discovery
  • Persistent Advancements in Genetics Space and Subsequent Growth in Precision Medicine Augur Well for iPSCs Market
  • Global Precision Medicine Market (In US$ Billion) for the Years 2018, 2021 & 2024
  • Increasing Prevalence of Chronic Disorders Supports Growth of iPSCs Market
  • Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
  • Number of New Cancer Cases Reported (in Thousands) by Cancer Type: 2018
  • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • Rising Diabetes Prevalence Presents Opportunity for iPSCs Market: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
  • Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for iPSCs Market
  • Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
  • Growth in Number of Genomics Projects Propels Market Growth
  • Genomic Initiatives in Select Countries
  • New Gene-Editing Tools Spur Interest and Investments in Genetics, Driving Lucrative Growth Opportunities for iPSCs: Total VC Funding (In US$ Million) in Genetics for the Years 2014, 2015, 2016, 2017 and 2018
  • Launch of Numerous iPSCs-Related Clinical Trials Set to Benefit Market Growth
  • Number of Induced Pluripotent Stem Cells based Studies by Select Condition: As on Oct 31, 2020
  • iPSCs-based Clinical Trial for Heart Diseases
  • Induced Pluripotent Stem Cells for Stroke Treatment
  • ‘Off-the-shelf' Stem Cell Treatment for Cancer Enters Clinical Trial
  • iPSCs for Hematological Disorders
  • Market Benefits from Growing Funding for iPSCs-Related R&D Initiatives
  • Stem Cell Research Funding in the US (in US$ Million) for the Years 2016 through 2021
  • Human iPSC Banks: A Review of Emerging Opportunities and Drawbacks
  • Human iPSC Banks Worldwide: An Overview
  • Cell Sources and Reprogramming Methods Used by Select iPSC Banks
  • Innovations, Research Studies & Advancements in iPSCs
  • Key iPSC Research Breakthroughs for Regenerative Medicine
  • Researchers Develop Novel Oncogene-Free and Virus-Free iPSC Production Method
  • Scientists Study Concerns of Genetic Mutations in iPSCs
  • iPSCs Hold Tremendous Potential in Transforming Research Efforts
  • Researchers Highlight Potential Use of iPSCs for Developing Novel Cancer Vaccines
  • Scientists Use Machine Learning to Improve Reliability of iPSC Self-Organization
  • STEMCELL Technologies Unveils mTeSR™ Plus
  • Challenges and Risks Related to Pluripotent Stem Cells
  • A Glance at Issues Related to Reprogramming of Adult Cells to iPSCs
  • A Note on Legal, Social and Ethical Considerations with iPSCs
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 2: World 5-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2025
  • Table 3: World Recent Past, Current & Future Analysis for Vascular Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 4: World 5-Year Perspective for Vascular Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
  • Table 5: World Recent Past, Current & Future Analysis for Cardiac Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 6: World 5-Year Perspective for Cardiac Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
  • Table 7: World Recent Past, Current & Future Analysis for Neuronal Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 8: World 5-Year Perspective for Neuronal Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
  • Table 9: World Recent Past, Current & Future Analysis for Liver Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 10: World 5-Year Perspective for Liver Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
  • Table 11: World Recent Past, Current & Future Analysis for Immune Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 12: World 5-Year Perspective for Immune Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
  • Table 13: World Recent Past, Current & Future Analysis for Other Cell Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 14: World 5-Year Perspective for Other Cell Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
  • Table 15: World Recent Past, Current & Future Analysis for Cellular Reprogramming by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 16: World 5-Year Perspective for Cellular Reprogramming by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
  • Table 17: World Recent Past, Current & Future Analysis for Cell Culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 18: World 5-Year Perspective for Cell Culture by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
  • Table 19: World Recent Past, Current & Future Analysis for Cell Differentiation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 20: World 5-Year Perspective for Cell Differentiation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
  • Table 21: World Recent Past, Current & Future Analysis for Cell Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 22: World 5-Year Perspective for Cell Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
  • Table 23: World Recent Past, Current & Future Analysis for Cellular Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 24: World 5-Year Perspective for Cellular Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
  • Table 25: World Recent Past, Current & Future Analysis for Other Research Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 26: World 5-Year Perspective for Other Research Methods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
  • Table 27: World Recent Past, Current & Future Analysis for Drug Development & Toxicology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 28: World 5-Year Perspective for Drug Development & Toxicology Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
  • Table 29: World Recent Past, Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 30: World 5-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
  • Table 31: World Recent Past, Current & Future Analysis for Regenerative Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 32: World 5-Year Perspective for Regenerative Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
  • Table 33: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2025 and % CAGR
  • Table 34: World 5-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2025
III. MARKET ANALYSIS
UNITED STATES
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
CANADA
JAPAN
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
CHINA
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
EUROPE
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
FRANCE
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
GERMANY
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
ITALY
UNITED KINGDOM
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
REST OF EUROPE
ASIA-PACIFIC
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
REST OF WORLD
IV. COMPETITION
  • Total Companies Profiled: 51

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Axol Bioscience Ltd.
  • Cynata Therapeutics Limited
  • Evotec SE
  • Fate Therapeutics, Inc.
  • FUJIFILM Cellular Dynamics, Inc.
  • Ncardia
  • Pluricell Biotech
  • REPROCELL USA, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • ViaCyte, Inc.